Therapy Detail

Therapy Name Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab
Synonym
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Fluorouracil Adrucil 5-FU Chemotherapy - Antimetabolite 10 Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth (NCI Drug Dictionary). Fluorouracil is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).
Irinotecan Camptosar CPT-11|Onivyde TOPO1 inhibitor 7 Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death (NCI Drug Dictionary). Camptosar (irinotecan) is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).
Oxaliplatin Eloxatin Diaminocyclohexane Oxalatoplatinum Chemotherapy - Platinum 6 Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity (NCI Drug Dictionary). Eloxatin (oxaliplatin) is FDA approved for colorectal cancer (FDA.gov).
Panitumumab Vectibix ABX-EGF EGFR Antibody 27 Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G12X colorectal cancer no benefit Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab Phase III Actionable In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920). 26341920
KRAS wild-type colorectal cancer sensitive Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab Phase III Actionable In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920). 26341920
KRAS wild-type colorectal cancer sensitive Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab Phase III Actionable In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with KRAS exon 2 wild-type colorectal cancer compared to FOLFIRI treatment alone, with an overall response rate of 35% (105/297) with the combination versus 10% (28/285) with FOLFIRI alone (PMID: 26341920). 26341920
KRAS G13X colorectal cancer no benefit Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab Phase III Actionable In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920). 26341920
KRAS mutant colorectal cancer no benefit Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab Phase III Actionable In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with KRAS mutations (PMID: 26341920). 26341920
Clinical Trial Phase Therapies Title Recruitment Status